Indivior PLC Ordinary Shares (INDV)vsMerck & Company Inc (MRK)
INDV
Indivior PLC Ordinary Shares
$36.78
+7.70%
HEALTHCARE · Cap: $4.18B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5147% more annual revenue ($65.01B vs $1.24B). MRK leads profitability with a 28.1% profit margin vs 17.0%. MRK trades at a lower P/E of 15.2x. INDV earns a higher WallStSmart Score of 62/100 (C+).
INDV
Buy62
out of 100
Grade: C+
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.5%
Fair Value
$22.49
Current Price
$36.78
$14.29 premium
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 37.1%
Earnings expanding 376.2% YoY
19.7% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
INDV profiles as a growth stock while MRK is a value play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.21 — expect wider price swings.
INDV is growing revenue faster at 19.7% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
INDV scores higher overall (62/100 vs 59/100), backed by strong 17.0% margins and 19.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?